A pilot study to determine the safety of argatroban injection in combination with rt-PA [recombinant tissue plasminogen activator, alteplase] in patients with acute ischemic stroke

Trial Profile

A pilot study to determine the safety of argatroban injection in combination with rt-PA [recombinant tissue plasminogen activator, alteplase] in patients with acute ischemic stroke

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Argatroban (Primary) ; Alteplase
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Acronyms ARTSS
  • Most Recent Events

    • 19 Oct 2010 Planned end date changed from 1 Dec 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 19 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 May 2010 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top